<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03436329</url>
  </required_header>
  <id_info>
    <org_study_id>TSCI005</org_study_id>
    <nct_id>NCT03436329</nct_id>
  </id_info>
  <brief_title>Reduced Dissemination of Tumor Cells With Primary Ligation of the Vein in Patients With Lung Cancer</brief_title>
  <official_title>Reduced Dissemination of Tumor Cells With Primary Ligation of the Vein in Patients With Lung Cancer: A Multi-centre Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of the sequence of vessel interruption in
      lung cancer patients on tumor cell spread and patient survival by using peripheral blood
      circulating tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Circulating tumor cells (CTCs) in the peripheral blood can be a biomarker to predict tumor
      recurrence and survival. Handling the tumor during a surgery may promote the release of CTCs
      into the bloodstream. Therefore, in a surgery of cancer, interruption of the vein before
      ligation of the artery may be justified. This multi-center randomized controlled trial is to
      assess the impact of the sequence of vessel interruption in lung cancer patients on tumor
      cell spread and patient survival by using peripheral blood CTCs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of the level of circulating tumor cells in the peripheral blood</measure>
    <time_frame>Intraoperative</time_frame>
    <description>The changes of the level of circulating tumor cells in the peripheral blood before cutting the skin and after closing the chest</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year Progression-Free-Survival</measure>
    <time_frame>From date of the recruitment, assessed up to 36 months</time_frame>
    <description>From the date of recruitment until the date of progression of lung cancer assessed up to 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>During the surgery</time_frame>
    <description>Blood loss during the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>During the surgery</time_frame>
    <description>Operative time during the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>From date of admission until the date of discharging or date of death from any cause in hospital, whichever came first, assessed up to 30 days</time_frame>
    <description>The length of patients staying in hospital from the date of checking in to the date of checking out</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Within 30 days after surgery</time_frame>
    <description>Complications resulting from surgery, such as pneumonia, air leak and arrhythmia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Surgery</condition>
  <condition>Circulating Tumor Cell</condition>
  <arm_group>
    <arm_group_label>Vein ligation first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artery ligation first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vein ligation first</intervention_name>
    <description>During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.</description>
    <arm_group_label>Vein ligation first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Artery ligation first</intervention_name>
    <description>During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.</description>
    <arm_group_label>Artery ligation first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with stage I-IV lung cancer eligible for surgery

          2. Patients undergoing the completely thoracoscopic lobectomy

          3. The nodule size was more than 2.5 cm

          4. Patients consenting for intraoperative blood sampling

        Exclusion Criteria:

          1. Patients who underwent primary wedge resection and open lobectomy

          2. Patients who received neoadjuvant therapy before surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lunxu Liu, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lunxu Liu, M.D.,Ph.D.</last_name>
    <phone>+86 28 85422494</phone>
    <email>lunxu_liu@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shiyou Wei, M.Sc.</last_name>
    <phone>+86 28 85422494</phone>
    <email>weishiyouscu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chendu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lunxu Liu, M.D.,Ph.D.</last_name>
      <phone>+86 28 85422494</phone>
      <email>lunxu_liu@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Shiyou Wei, M.Sc.</last_name>
      <phone>+86 28 85422494</phone>
      <email>weishiyouscu@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gall TM, Jacob J, Frampton AE, Krell J, Kyriakides C, Castellano L, Stebbing J, Jiao LR. Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. JAMA Surg. 2014 May;149(5):482-5.</citation>
    <PMID>24599353</PMID>
  </reference>
  <reference>
    <citation>Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K. Tumor cells in blood shed from the surgical field. Arch Surg. 1995 Apr;130(4):387-93.</citation>
    <PMID>7710337</PMID>
  </reference>
  <reference>
    <citation>Li F, Jiang G, Chen Y, Wang J. Curative Effects of Different Sequences of Vessel Interruption During the Completely Thoracoscopic Lobectomy on Early Stage Non-Small Cell Lung Cancer. Ann Thorac Cardiovasc Surg. 2015;21(6):536-43. doi: 10.5761/atcs.oa.15-00044. Epub 2015 Aug 18.</citation>
    <PMID>26289504</PMID>
  </reference>
  <reference>
    <citation>Kozak A, Alchimowicz J, Safranow K, Wójcik J, Kochanowski L, Kubisa B, Pieróg J, Grodzki T. The impact of the sequence of pulmonary vessel ligation during anatomic resection for lung cancer on long-term survival--a prospective randomized trial. Adv Med Sci. 2013;58(1):156-63. doi: 10.2478/v10039-012-0061-3.</citation>
    <PMID>23612700</PMID>
  </reference>
  <reference>
    <citation>Refaely Y, Sadetzki S, Chetrit A, Simansky DA, Paley M, Modan B, Yellin A. The sequence of vessel interruption during lobectomy for non-small cell lung cancer: is it indeed important? J Thorac Cardiovasc Surg. 2003 Jun;125(6):1313-20.</citation>
    <PMID>12830050</PMID>
  </reference>
  <reference>
    <citation>Kurusu Y, Yamashita J, Hayashi N, Mita S, Fujino N, Ogawa M. The sequence of vessel ligation affects tumor release into the circulation. J Thorac Cardiovasc Surg. 1998 Jul;116(1):107-13.</citation>
    <PMID>9671904</PMID>
  </reference>
  <reference>
    <citation>Ge MJ, Shi D, Wu QC, Wang M, Li LB. Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period. J Cancer Res Clin Oncol. 2006 Apr;132(4):248-56. Epub 2005 Dec 1.</citation>
    <PMID>16320073</PMID>
  </reference>
  <reference>
    <citation>Yellin A, Sadetzki S, Simansky DA, Refaely Y, Chetrit A, Paley M. The sequence of vessel interruption during lobectomy: does it affect the amount of blood retained in the lobe? Eur J Cardiothorac Surg. 2007 Apr;31(4):711-3. Epub 2007 Feb 15.</citation>
    <PMID>17306554</PMID>
  </reference>
  <reference>
    <citation>Hashimoto M, Tanaka F, Yoneda K, Takuwa T, Matsumoto S, Okumura Y, Kondo N, Tsubota N, Tsujimura T, Tabata C, Nakano T, Hasegawa S. Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. Interact Cardiovasc Thorac Surg. 2014 Jun;18(6):775-83. doi: 10.1093/icvts/ivu048. Epub 2014 Mar 11.</citation>
    <PMID>24618055</PMID>
  </reference>
  <reference>
    <citation>Song PP, Zhang W, Zhang B, Liu Q, DU J. Effects of different sequences of pulmonary artery and vein ligations during pulmonary lobectomy on blood micrometastasis of non-small cell lung cancer. Oncol Lett. 2013 Feb;5(2):463-468. Epub 2012 Nov 9.</citation>
    <PMID>23420582</PMID>
  </reference>
  <reference>
    <citation>Ackerman NB. Primary arterial ligation in resection of cancer of the colon. Rational and technic. Am J Surg. 1977 Jan;133(1):73-7.</citation>
    <PMID>835783</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2018</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Lunxu Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Surgical technique</keyword>
  <keyword>vessel ligation</keyword>
  <keyword>Circulating tumor cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

